Pharmaceutical Industry Blog

Last Updated: July 21, 2026 TL;DR: Madagascar is a market of roughly 33.5 million people in which essentially every sterile injectable is imported. The national regulator's own register of licensed manufacturers lists just three companies — FARMAD, HOMEOPHARMA and PHARMALAGASY — and none of them produces sterile injectables. Demand is severe and rising: malaria cases quadrupled between 2019 and 2024 to an estimated 8.17 million with 20,903 deaths, maternal mortality stands at

Last Updated: July 21, 2026 TL;DR: Peru is a market of roughly 35 million people that imports around two-thirds of the medicines it consumes, with domestic production estimated at about a third of the total and shrinking. Cancer is now the country's leading cause of death, anaemia affects 43.4% of children aged 6 to 35 months, and tuberculosis notifications reached 33,049 in 2024 — all of which sustain steady demand for sterile injectables across oncology, anti-infectives, pa

Last Updated: July 20, 2026 TL;DR: Saudi Arabia — a market of roughly 35 million people, more than 40% of them expatriates, accounting for around 60% of GCC healthcare expenditure and pharmaceutical purchasing — is regulated by one of the most capable authorities in the region. The Saudi Food and Drug Authority reached WHO Global Benchmarking Tool Maturity Level 4 in October 2023, the first in the Eastern Mediterranean Region and third worldwide to do so. Marketing authorisat

Last Updated: July 20, 2026 TL;DR: Malaysia — a 34.4 million-population upper-middle-income market served by roughly 149 Ministry of Health hospitals and more than 200 licensed private hospitals — runs one of the more demanding medicine regulatory systems in Southeast Asia, and any injectable supplier that treats it casually will not get through the door. Product registration is granted by the Drug Control Authority (DCA) on the technical assessment of the National Pharmaceut

Last Updated: July 19, 2026 TL;DR: Ghana — a West African healthcare market served by a four-tier public network of teaching hospitals (Korle Bu, Komfo Anokye and Tamale), regional hospitals, district hospitals and CHPS compounds, financed in large part through the National Health Insurance Scheme — carries a dual disease burden of malaria, tuberculosis, cholera and diarrhoeal illness alongside non-communicable diseases that now account for an estimated 43% of deaths, and tha

Last Updated: July 19, 2026 TL;DR: Uzbekistan — Central Asia's most populous country, served by a Ministry of Health network that runs from republican specialised scientific-practical medical centres in Tashkent through regional (viloyat) multidisciplinary medical centres to district hospitals and rural physician points — imports more than 80% of the medicines its patients use, which puts a permanent premium on reliable, compliant sterile injectable supply. Every medicine pla